» Articles » PMID: 28853863

Nuclear and Mitochondrial DNA Methylation Patterns Induced by Valproic Acid in Human Hepatocytes

Overview
Specialty Toxicology
Date 2017 Aug 31
PMID 28853863
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Valproic acid (VPA) is one of the most widely prescribed antiepileptic drugs in the world. Despite its pharmacological importance, it may cause liver toxicity and steatosis through mitochondrial dysfunction. The aim of this study is to further investigate VPA-induced mechanisms of steatosis by analyzing changes in patterns of methylation in nuclear DNA (nDNA) and mitochondrial DNA (mtDNA). Therefore, primary human hepatocytes (PHHs) were exposed to an incubation concentration of VPA that was shown to cause steatosis without inducing overt cytotoxicity. VPA was administered daily for 5 days, and this was followed by a 3 day washout (WO). Methylated DNA regions (DMRs) were identified by using the methylated DNA immunoprecipitation-sequencing (MeDIP-seq) method. The nDNA DMRs after VPA treatment could indeed be classified into oxidative stress- and steatosis-related pathways. In particular, networks of the steatosis-related gene EP300 provided novel insight into the mechanisms of toxicity induced by VPA treatment. Furthermore, we suggest that VPA induces a crosstalk between nDNA hypermethylation and mtDNA hypomethylation that plays a role in oxidative stress and steatosis development. Although most VPA-induced methylation patterns appeared reversible upon terminating VPA treatment, 31 nDNA DMRs (including 5 zinc finger protein genes) remained persistent after the WO period. Overall, we have shown that MeDIP-seq analysis is highly informative in disclosing novel mechanisms of VPA-induced toxicity in PHHs. Our results thus provide a prototype for the novel generation of interesting methylation biomarkers for repeated dose liver toxicity in vitro.

Citing Articles

Identification of common genetic factors and immune-related pathways associating more than two autoimmune disorders: implications on risk, diagnosis, and treatment.

Rajalingam A, Ganjiwale A Genomics Inform. 2024; 22(1):10.

PMID: 38956704 PMC: 11221123. DOI: 10.1186/s44342-024-00004-5.


Valproic acid regulates the miR-155/Jarid2 axis by affecting miR-155 promoter methylation in glioma.

Wang R, Chen Y, Kuang W, Jiang W, Zeng W, Chen Y Acta Biochim Biophys Sin (Shanghai). 2024; 56(2):174-183.

PMID: 38273784 PMC: 10984859. DOI: 10.3724/abbs.2023259.


The mitoepigenome responds to stress, suggesting novel mito-nuclear interactions in vertebrates.

Lees J, Pertille F, Lotvedt P, Jensen P, Bosagna C BMC Genomics. 2023; 24(1):561.

PMID: 37736707 PMC: 10515078. DOI: 10.1186/s12864-023-09668-9.


Involvement of oxidative species in cyclosporine-mediated cholestasis.

Nsengimana B, Okpara E, Hou W, Yan C, Han S Front Pharmacol. 2022; 13:1004844.

PMID: 36425570 PMC: 9679297. DOI: 10.3389/fphar.2022.1004844.


Mitochondrial DNA: Consensuses and Controversies.

Shokolenko I, Alexeyev M DNA (Basel). 2022; 2(2):131-148.

PMID: 36381197 PMC: 9648901. DOI: 10.3390/dna2020010.


References
1.
Cadenas E, Davies K . Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med. 2000; 29(3-4):222-30. DOI: 10.1016/s0891-5849(00)00317-8. View

2.
Chang T, Abbott F . Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity. Drug Metab Rev. 2006; 38(4):627-39. DOI: 10.1080/03602530600959433. View

3.
Gim J, Hong C, Kim D, Moon J, Choi Y, Eo J . Genome-wide analysis of DNA methylation before-and after exercise in the thoroughbred horse with MeDIP-Seq. Mol Cells. 2015; 38(3):210-20. PMC: 4363720. DOI: 10.14348/molcells.2015.2138. View

4.
Goel A, Boland C . Epigenetics of colorectal cancer. Gastroenterology. 2012; 143(6):1442-1460.e1. PMC: 3611241. DOI: 10.1053/j.gastro.2012.09.032. View

5.
Mishra S, Singh P, Rath S . Protective effect of quercetin on chloroquine-induced oxidative stress and hepatotoxicity in mice. Malar Res Treat. 2013; 2013:141734. PMC: 3625570. DOI: 10.1155/2013/141734. View